Am-461

Am-461

SCHEMBL14715970

COc1ccc(CC(=O)[O-])cc1Oc1ccc(NC(=O)C(C)(C)C)cc1CSC(C)(C)C.[Na+]

nearest known ligand 0.84

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

PTGDR2

The experimentally established mechanism targets of Am-461. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PTGDR2 known ✓ Q9Y5Y4 4/20 0.39
CYP3A4 P08684 1/20 0.84
EPHX2 P34913 1/20 0.40
GNRHR P30968 1/20 0.40
CYP1A2 P05177 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
LMNA P02545 4/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
HTT P42858 2/20 0.39
STAT3 P40763 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
KMT2A Q03164 2/20 0.39
MEN1 O00255 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.37
KDM4E B2RXH2 1/20 0.37
POLB P06746 1/20 0.36
BCHE P06276 1/20 0.36
ACHE P22303 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14733229 0.91 CYP3A4 (0.85) CYP3A4EPHX2GNRHRCYP1A2CYP2C9
SCHEMBL2361747 0.91 CYP3A4 (0.85) CYP3A4EPHX2GNRHRCYP1A2CYP2C9
Am-461 SCHEMBL349848 0.91 CYP3A4 (1.00) CYP3A4EPHX2CYP1A2CYP2C9CYP2C19
Am-461 SCHEMBL29567409 0.91 CYP3A4 (1.00) CYP3A4EPHX2CYP1A2CYP2C9CYP2C19
Am-461 SCHEMBL14715969 0.90 CYP3A4 (0.98) CYP3A4EPHX2CYP1A2CYP2C9CYP2C19
Am-461 SCHEMBL14715972 0.90 CYP3A4 (0.98) CYP3A4EPHX2CYP1A2CYP2C9CYP2C19
SCHEMBL14733252 0.89 CYP3A4 (0.81) CYP3A4EPHX2GNRHRCYP1A2CYP2C9
SCHEMBL349965 0.88 CYP3A4 (0.80) CYP3A4EPHX2GNRHRCYP1A2CYP2C9
SCHEMBL14733251 0.87 CYP3A4 (0.78) CYP3A4EPHX2LMNASMN1; SMN2HTT
SCHEMBL14733237 0.86 CYP3A4 (0.77) CYP3A4EPHX2GNRHRLMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9688624-B2 DP2 antagonist and uses thereof BRICKELL BIOTECH, INC. (US) 2017-06-27 US disclosed
US-20130053444-A1 DP2 ANTAGONIST AND USES THEREOF PANMIRA PHARMACEUTICALS, LLC (US) 2013-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130053444-A1 DP2 ANTAGONIST AND USES THEREOF PTGER2, PTGDR2, PTGES2 PTGDR2 2/4885CYP3A4 2497/4885EPHX2 218/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.